{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:51:13Z","timestamp":1764276673108},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.2165\/11586310-000000000-00000","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T21:10:56Z","timestamp":1362517856000},"page":"225-242","source":"Crossref","is-referenced-by-count":24,"title":["Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-\u03b2-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects"],"prefix":"10.1007","volume":"10","author":[{"given":"Teresa","family":"Nunes","sequence":"first","affiliation":[]},{"given":"Jos\u00e9 F.","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Vaz-da-Silva","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Igreja","sequence":"additional","affiliation":[]},{"given":"Lyndon C.","family":"Wright","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Patricio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,11,25]]},"reference":[{"issue":"7Suppl.4","key":"10040225_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-200000004-00001","volume":"35","author":"M Esler","year":"2000","unstructured":"Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 2000; 35 (7 Suppl. 4): S1\u20137","journal-title":"J Cardiovasc Pharmacol"},{"issue":"12","key":"10040225_CR2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ejheart.2008.09.013","volume":"10","author":"G Grassi","year":"2008","unstructured":"Grassi G, Bolla G, Quarti-Trevano F, et al. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 2008 Dec; 10 (12): 1186\u201391","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10040225_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1113\/expphysiol.2009.047381","volume":"95","author":"G Grassi","year":"2010","unstructured":"Grassi G, Seravalle G, Quarti-Trevano F. The \u2018neuroadrenergic hypothesis\u2019 in hypertension: current evidence. Exp Physiol 2010 Dec 11; 95 (5): 581\u20136","journal-title":"Exp Physiol"},{"issue":"4","key":"10040225_CR4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.AACN.0000340718.93742.c4","volume":"19","author":"CS Lee","year":"2008","unstructured":"Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care 2008 Oct-Dec; 19 (4): 364\u201385","journal-title":"AACN Adv Crit Care"},{"issue":"4Pt2","key":"10040225_CR5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.HYP.34.4.724","volume":"34","author":"G Mancia","year":"1999","unstructured":"Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34 (4 Pt 2): 724\u20138","journal-title":"Hypertension"},{"issue":"8","key":"10040225_CR6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/clc.4960180804","volume":"18","author":"WW Parmley","year":"1995","unstructured":"Parmley WW. Neuroendocrine changes in heart failure and their clinical relevance. Clin Cardiol 1995; 18 (8): 440\u20135","journal-title":"Clin Cardiol"},{"issue":"21","key":"10040225_CR7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJM199605233342109","volume":"334","author":"MA Pfeffer","year":"1996","unstructured":"Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure. N Engl J Med 1996; 334 (21): 1396\u20137","journal-title":"N Engl J Med"},{"issue":"8","key":"10040225_CR8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/sj.bjp.0701315","volume":"121","author":"WC Stanley","year":"1997","unstructured":"Stanley WC, Li B, Bonhaus DW, et al. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 1997; 121 (8): 1803\u20139","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10040225_CR9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2174\/138161280406221011113124","volume":"4","author":"SS Hegde","year":"1998","unstructured":"Hegde SS, Friday KF. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Curr Pharm Des 1998; 4 (6): 469\u201379","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10040225_CR10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00512932","volume":"333","author":"P Soares-da-Silva","year":"1986","unstructured":"Soares-da-Silva P. Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol 1986 Jul; 333 (3): 219\u201323","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10040225_CR11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1476-5381.1987.tb16828.x","volume":"90","author":"P Soares-da-Silva","year":"1987","unstructured":"Soares-da-Silva P. A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol 1987 Jan; 90 (1): 91\u20138","journal-title":"Br J Pharmacol"},{"key":"10040225_CR12","unstructured":"Gomes P, Soares-da-Silva P. Dopamine. In: Baden M, editor. Cardiovascular hormone systems: from molecular mechanisms to novel therapeutics. Weinheim: Wiley-VCH, 2008: 251\u201393"},{"issue":"1","key":"10040225_CR13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00041552-200201000-00013","volume":"11","author":"PA Jose","year":"2002","unstructured":"Jose PA, Eisner GM, Felder RA. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2002 Jan; 11 (1): 87\u201392","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10040225_CR14","first-page":"55","volume":"25","author":"Y Ishii","year":"1975","unstructured":"Ishii Y, Fujii Y, Mimura C, et al. Pharmacological action of FD-008, a new dopamine beta-hydroxylase inhibitor: I, effects on blood pressure in rats and dogs. Arzneimittelforschung 1975; 25: 55\u20139","journal-title":"Arzneimittelforschung"},{"key":"10040225_CR15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/jm00386a008","volume":"30","author":"LI Kruse","year":"1987","unstructured":"Kruse LI, Kaiser C, DeWolf Jr WE, et al. Multisubstrate inhibitors of dopamine beta-hydroxylase: 2, structureactivity relationships at the phenethylamine binding site. J Med Chem 1987; 30: 486\u201394","journal-title":"J Med Chem"},{"key":"10040225_CR16","first-page":"554","volume":"241","author":"EH Ohlstein","year":"1987","unstructured":"Ohlstein EH, Kruse LI, Ezekiel M, et al. Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats. J Pharmacol Exp Ther 1987; 241: 554\u20139","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10040225_CR17","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/jm051051f","volume":"49","author":"A Beliaev","year":"2006","unstructured":"Beliaev A, Learmonth DA, Soares-da-Silva P. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine betahydroxylase. J Med Chem 2006; 49 (3): 1191\u20137","journal-title":"J Med Chem"},{"key":"10040225_CR18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1021\/jm00156a002","volume":"29","author":"LI Kruse","year":"1986","unstructured":"Kruse LI, Kaiser C, DeWolf Jr WE, et al. Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase. J Med Chem 1986; 29: 887\u20139","journal-title":"J Med Chem"},{"key":"10040225_CR19","first-page":"e133","volume":"50","author":"B Igreja","year":"2007","unstructured":"Igreja B, Wright L, Soares-Da-Silva P. Sustained antihypertensive effects of a selective peripheral dopamine-Xhydroxylase inhibitor [abstract]. Hypertension 2007; 50: e133","journal-title":"Hypertension"},{"key":"10040225_CR20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/157340809787314265","volume":"5","author":"A Beliaev","year":"2009","unstructured":"Beliaev A, Ferreira H, Learmonth DL, et al. Dopamine beta- monooxygenase: mechanism, substrates and inhibitors. Curr Enzyme Inh 2009; 5: 27\u201343","journal-title":"Curr Enzyme Inh"},{"key":"10040225_CR21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/0091270009339191","volume":"49","author":"T Nunes","year":"2009","unstructured":"Nunes T, Rocha JF, Almeida L, et al. A rising single oral dose study to investigate the tolerability and pharmacokinetics of etamicastat, a new dopamine beta-hydroxylase inhibitor, in healthy male volunteers [abstract]. J Clin Pharmacol 2009; 49: 1094","journal-title":"J Clin Pharmacol"},{"key":"10040225_CR22","first-page":"1095","volume":"49","author":"A Falcao","year":"2009","unstructured":"Falcao A, Nunes T, Rocha JF, et al. Comparative bioavailability study of etamicastat (BIA 5-453) under fasted and fed conditions [abstract]. J Clin Pharmacol 2009; 49: 1095","journal-title":"J Clin Pharmacol"},{"key":"10040225_CR23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/dmd.104.002998","volume":"33","author":"HR Winter","year":"2005","unstructured":"Winter HR, Unadkat JD. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos 2005; 33: 969\u201376","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10040225_CR24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/carcin\/22.9.1405","volume":"22","author":"S Fronhoffs","year":"2001","unstructured":"Fronhoffs S, Bruning T, Ortiz-Pallardo E, et al. Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck. Carcinogenesis 2001 Sep; 22 (9): 1405\u201312","journal-title":"Carcinogenesis"},{"issue":"6","key":"10040225_CR25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000072934","volume":"16","author":"H Brocvielle","year":"2003","unstructured":"Brocvielle H, Muret P, Goydadin AC, et al. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects. Skin Pharmacol Appl Skin Physiol 2003 Nov\u2013Dec; 16 (6): 386\u201392","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"issue":"1","key":"10040225_CR26","first-page":"22","volume":"58","author":"M Rychlik-Sych","year":"2006","unstructured":"Rychlik-Sych M, Skretkowicz J, Gawronska-Szklarz B, et al. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep 2006 Jan\u2013Feb; 58 (1): 22\u20139","journal-title":"Pharmacol Rep"},{"key":"10040225_CR27","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1136\/jmg.2003.009282","volume":"414","author":"J Deinum","year":"2004","unstructured":"Deinum J, Steenbergen-Spanjers GC, Jansen M, et al. DBH gene variants that cause low plasma dopamine beta hydroxylase with or without a severe orthostatic syndrome [letter]. J Med Genet 2004 Apr; 41 (4): e38","journal-title":"J Med Genet"},{"issue":"6","key":"10040225_CR28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920008784892065","volume":"9","author":"JM Walraven","year":"2008","unstructured":"Walraven JM, Zang Y, Trent JO, et al. Structure\/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 2008 Jul; 9 (6): 471\u201386","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10040225_CR29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/03602530701852917","volume":"40","author":"JM Walraven","year":"2008","unstructured":"Walraven JM, Trent JO, Hein DW. Structure-function analyses of single nucleotide polymorphisms in human Nacetyltransferase 1. Drug Metab Rev 2008; 40 (1): 169\u201384","journal-title":"Drug Metab Rev"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2165\/11586310-000000000-00000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T23:10:24Z","timestamp":1688080224000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/11586310-000000000-00000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10040225"],"URL":"https:\/\/doi.org\/10.2165\/11586310-000000000-00000","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}